Company: BDRX
Filing Date: 2025-12-11
Form Type: F-1/A
Source: 0001214659-25-017944
Chunk: 30

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-11
Form: F-1/A
Chunk 30
---
 |
| Decrease to net tangible book value per Depositary Share attributable to investors purchasing our Depositary Shares in this offering |     | $                     | (7.54 | ) |
| As adjusted net tangible book value per Depositary Share as of June 30, 2025, after giving effect to this offering                   |     | $                     |  4.65 |   |
| Accretion per Depositary Share to the investors in this offering                                                                     |     | $                     |  0.58 |   |

A
$1.00 increase in the assumed combined public offering price of $4.07 per Unit would increase the as adjusted net tangible book
value per Depositary Share by $0.81 and increase the accretion per Depositary Share to investors participating in this offering by $0.81,
assuming no sale of any Pre-Funded Units and no exercise of the Series L Warrants and Placement Agent Warrants, and after deducting estimated
placement agent fees and estimated offering expenses payable by us. A $1.00 decrease in the assumed combined public offering price
of $4.07 per Unit would decrease the as adjusted net tangible book value per Depositary Share by $0.81 and decrease the accretion
per Depositary Share to investors participating in this offering by $0.81, assuming no sale of any Units containing Pre-Funded Warrants
and no exercise of the Series L Warrants and Placement Agent Warrants, and after deducting estimated placement agent fees and estimated
offering expenses payable by us.

For purposes of this section,
the share information above excludes:

| · | 313,070,788 Ordinary Shares issuable upon the exercise of stock options outstanding under our equity incentive plans at a weighted-average 
 exercise price of £0.005 per share;                                                                                                        |

| 21 |

| · | six Ordinary Shares issuable upon the exercise of stock options in connection with the acquisition of DARA Bioscience, Inc. at a weighted 
 average exercise price of $981.91 per share; and                                                                                          |

| · | warrants, including pre-funded warrants, exercisable for 48,848 Depositary Shares (representing 4,884,800,000 Ordinary Shares), at 
 a weighted average exercise price of $402.20 per Depositary Share.                                                                 |

The information discussed
above is illustrative only and will be adjusted based on the actual public offering price, the actual number of units that we offer in
this offering,